Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2016 / Articles / Oct / And the Facility of the Year is…
Manufacture Business Practice Technology and Equipment Small Molecules Trends & Forecasts Facilities & Equipment Technology & Manufacturing Small Molecules

And the Facility of the Year is…

Genentech’s Cell Culture Biologics Drug Substance Plant 2 in Vacaville, California

By Stephanie Vine 10/20/2016 1 min read

Share

Congratulations to Genentech, which is the overall winner of the International Society for Pharmaceutical Engineering’s (ISPE) 2016 Facility of the Year Awards (FOYA). The winning project? A revamp and restart of the company’s Cell Culture Biologics Drug Substance Plant 2 (CCP2) in Vacaville, California, which supports the production of oncology drugs – a market that has tripled in recent years. According to ISPE, the project “exemplifies the FOYA program commitment to innovate and advance pharmaceutical manufacturing technology” (1).

The Vacaville facility was by no-means an “old facility”. Constructed in the 2000s, the plant was closed in 2010 before it produced a single product; the merger of Roche and Genentech resulted in excess capacity. In 2013, the facility was given a new lease of life thanks to rising demand for the companies’ oncology drugs. Over the last few years, Genentech has been busy upgrading the site with improvements in environmental microbial control, manufacturing control and automation. The project – led by Chris Schreil, Senior Principal Engineer/Project Advisor at Genentech – was completed two months ahead of schedule and within the planned budget. The facility reopened in January 2015 and uses some of the largest scale cell culture production equipment in the industry (8 x 25,000-L bioreactors; 1.8 m diameter chromatography columns; seven clean-in-place skids for both upstream and downstream areas). As well as being the overall winner for FOYA, the company won the Process Innovation category. It’s not the first time that Genentech has been the overall winner of FOYA – it also came out on top in 2007 for its Oceanside, California, facility and in 2010 for its Tuas facility in Singapore. Genentech’s parent company, Roche, has also received a number of FOYA category awards over the years, as well as being declared the overall winner in 2009. The individual category winners for FOYA 2016 were announced at the start of the year.

  • Process Innovation, Genentech, Cell Culture Biologics Drug Substance Plant 2, USA
  • Equipment Innovation, Pfizer, Portable Continuous Miniature and Modular Collaboration, USA
  • Facility Integration, Takara Bio, Center for Gene and Cell Processing Construction, Japan
  • Operational Excellence, Baxter BioPharma Solutions, Oncology Manufacturing Expansion, Germany
  • Project Execution, Janssen Vaccines, ZEBOV in 81J project, Switzerland
  • Sustainability, Ethicon, San Lorenzo Conservation Strategy, Puerto Rico
Honorable Mentions were also awarded to three companies for separate projects: Greater Pharma Manufacturing, Thailand; University of Strathclyde, UK; and West Pharmaceutical Services, 
USA.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. ISPE, “ISPE names 2016 Facility of the Year Awards Overall Winner”, (2016). Available at: http://bit.ly/2exm7hT. Accessed October 17, 2016.

About the Author(s)

Stephanie Vine

Making great scientific magazines isn’t just about delivering knowledge and high quality content; it’s also about packaging these in the right words to ensure that someone is truly inspired by a topic. My passion is ensuring that our authors’ expertise is presented as a seamless and enjoyable reading experience, whether in print, in digital or on social media. I’ve spent fourteen years writing and editing features for scientific and manufacturing publications, and in making this content engaging and accessible without sacrificing its scientific integrity. There is nothing better than a magazine with great content that feels great to read.

More Articles by Stephanie Vine

False

Advertisement

Recommended

False

Related Content

What Trump’s Latest Moves Mean for the Industry
Business Practice Standards & Regulation Trends & Forecasts Bioprocessing - Upstream & Downstream
What Trump’s Latest Moves Mean for the Industry

May 27, 2025

6 min read

Audrey Greenberg’s latest insight on US-based manufacturing, Trump’s “Administration for A Healthy America”, and an ever-shifting regulatory environment.

Big Bad Pharma?
Business Practice Trends & Forecasts
Big Bad Pharma?

December 1, 2014

0 min read

The Ebola media frenzy has reminded the public how selfish our industry is. But, somehow, that doesn’t sound quite right...

Access All Areas
Business Practice Trends & Forecasts
Access All Areas

December 1, 2014

0 min read

The 2014 Access to Medicine index shows progress – but companies remain “conservative”

Care to ‘Patent Dance’?
Business Practice Trends & Forecasts
Care to ‘Patent Dance’?

December 1, 2014

0 min read

Amgen accuses Sandoz of snubbing its advances in a complex biosimilar dispute

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.